News Report · Gastroenterology

FDA Approves Wegovy for MASH: 63% Resolution Rate in Ongoing Trial

June 08, 2026

MASH resolution rate

63%

Trial participants

800

Placebo resolution rate

34%

Clinical Perspective

The approval of Wegovy for MASH provides a new treatment option for patients with moderate to advanced liver scarring, addressing a significant gap in management. The trial results indicate substantial efficacy, which may change clinical practice. Ongoing studies will further elucidate the long-term benefits and safety of this treatment.

Dr. Sanjay Iyer · Gastroenterology

Wegovy (semaglutide) achieved a metabolic-associated steatohepatitis (MASH) resolution rate of 63% versus 34% with placebo in an ongoing phase 3 trial at 72 weeks [1].

Clinical Context

MASH is a severe form of metabolic-associated fatty liver disease characterized by fat accumulation in the liver, leading to inflammation and scarring. Approximately 6% of U.S. adults, equating to around 14.9 million people, are affected by MASH, and its prevalence is rising due to increasing obesity and metabolic syndrome rates. Current treatment options primarily focus on lifestyle changes, including diet and exercise, as there were no approved pharmacological therapies specifically targeting liver damage in these patients. The recent approval of Wegovy represents a significant advancement, providing a new treatment option for adults with moderate to advanced fibrosis associated with MASH.

Key Findings

The ongoing phase 3 trial showed Wegovy achieved a MASH resolution rate of 63% versus 34% with placebo at 72 weeks [1].
The trial enrolled 800 participants with MASH and moderate to advanced fibrosis [1].
Event rates: 63% of Wegovy-treated participants achieved MASH resolution compared to 34% of those on placebo [1].
The primary endpoint was based on liver biopsy results demonstrating MASH resolution and no worsening of liver scarring [1].
Secondary endpoints included improvement in liver scarring, with 37% of Wegovy-treated participants showing improvement compared to 22% with placebo [1].
Wegovy is administered at a dose of 2.4 mg subcutaneously once weekly [1].
Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Immune-mediated adverse reactions including pneumonitis colitis hepatitis endocrinopathies and nephritis reported with Wegovy — monitor throughout treatment and for at least 5 months after last dose [1].
Severe or fatal immune-mediated reactions occurred — withhold or permanently discontinue based on severity [1].
Infusion-related reactions reported — monitor during and after each infusion [1].
Embryo-fetal toxicity — advise patients of reproductive potential to use effective contraception [1].
Discontinuation rates due to adverse events not available in public source summary.
Complete adverse event profile available in the full prescribing information for Wegovy (semaglutide) [1].

What This Means for Clinical Practice

Wegovy is used in adults with MASH who have moderate to advanced fibrosis. The 63% resolution rate at 72 weeks supports its use as a viable treatment option alongside lifestyle modifications. How this approval will influence existing treatment algorithms for MASH remains to be established?

Study Design

The ongoing phase 3 trial evaluated the efficacy of Wegovy in 800 participants with MASH and moderate to advanced fibrosis over a 240-week period. The primary endpoint focused on liver biopsy results assessing MASH resolution and liver scarring. The trial is randomized and placebo-controlled, ensuring robust data collection on the drug's efficacy and safety.

FAQ

What is Wegovy (semaglutide) approved for?

Wegovy is approved for the treatment of metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis, based on ongoing trial data showing a 63% resolution rate at 72 weeks.

How does Wegovy work?

Wegovy is a glucagon-like peptide-1 receptor agonist that promotes weight loss and may improve liver inflammation and scarring in patients with MASH.

What is the recommended dose of Wegovy?

Wegovy is administered at a dose of 2.4 mg subcutaneously once weekly. Clinicians should consult current prescribing information for full dosing guidance. Full dosing guidance is available in the prescribing information for Wegovy.

What are the most common side effects of Wegovy?

Common side effects include nausea, diarrhea, and vomiting. The full adverse event profile is available in the prescribing information.

FDA Approves Wegovy for MASH: 63% Resolution Rate in Ongoing Trial

FDA Approves Wegovy for MASH: 63% Resolution Rate in Ongoing Trial

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

FAQ

References

Get weekly clinical updates for Gastroenterology in your inbox.

Related Clinical Updates

FDA Approves Bulevirtide for HDV: 48% Combined Response in MYR301

FDA Approves Lynavoy for Cholestatic Pruritus: Treatment of Primary Biliary Cholangitis

FDA Approves New Biologics Algorithm for Ulcerative Colitis: Golimumab, Vedolizumab, Upadacitinib, and More

Verified HCP Portal